Scientists test 'Living' vaginal probiotic that could block HIV
NCT ID NCT07181486
Summary
This early-stage study is testing the safety of a vaginal probiotic called MucoCept-CVN, which is designed to prevent HIV infection in women. The probiotic contains a modified bacteria that continuously produces an anti-HIV drug. Researchers will enroll 12 healthy women to test different doses and monitor for side effects, how long the bacteria stays, and if it can be cleared with antibiotics if needed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV-1-INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
UCSF Zuckerberg San Francisco General Hospital
RECRUITINGSan Francisco, California, 94110, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.